{"doi":"10.1016/j.esmoop.2020.100028","title":"Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface","abstract":null,"journal":"ESMO Open","year":2021,"id":633680,"datarank":0.38474240361923057,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.0,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1643067,"name":"A. Caliò","orcid":null,"position":1,"is_corresponding":false},{"id":1643068,"name":"R. Giovannetti","orcid":null,"position":2,"is_corresponding":false},{"id":1643069,"name":"M. Motton","orcid":null,"position":3,"is_corresponding":false},{"id":1643070,"name":"R. Mazzarotto","orcid":null,"position":4,"is_corresponding":false},{"id":1643071,"name":"C. Micheletto","orcid":null,"position":5,"is_corresponding":false},{"id":1643072,"name":"M.V. Infante","orcid":null,"position":6,"is_corresponding":false},{"id":1643073,"name":"A. Scarpa","orcid":null,"position":7,"is_corresponding":false},{"id":1643074,"name":"M. Milella","orcid":null,"position":8,"is_corresponding":false},{"id":1643075,"name":"S. Pilotto","orcid":null,"position":9,"is_corresponding":false},{"id":1643066,"name":"L. Belluomini","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface","abstract":"With the introduction of the third-generation tyrosine kinase inhibitor (TKI) osimertinib for the first-line treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), understanding underlying mechanisms of resistance becomes crucial in order to optimize treatment strategy. Histological transformation towards both small-cell lung cancer (SCLC) and squamous cell carcinoma have been described as resistance patterns featuring peculiar molecular landscapes, potentially detectable at diagnosis and becoming clinically evident after clonal selection and disease evolution.","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33465742","pmcid":"PMC7814107","openalex_id":"https://openalex.org/W3122289400","authors":[],"funders":[],"total_grants":0,"fwci":0.7299,"citation_percentile":0.71836966,"influential_citations":0,"citation_trend":[{"year":2021,"count":3},{"year":2022,"count":1},{"year":2023,"count":2},{"year":2024,"count":3},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.esmoop.2020.100028","host_type":"journal"},{"url":"https://doi.org/10.1016/j.esmoop.2020.100028","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2059702920328933?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2059702920328933?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33465742","host_type":"repository"},{"url":"http://europepmc.org/pmc/articles/PMC7814107","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7814107","host_type":"repository"},{"url":"http://www.esmoopen.com/article/S2059702920328933/pdf","host_type":"Unpaywall"},{"url":"https://europepmc.org/articles/PMC7814107","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7814107?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Lung Cancer Research Studies","Lung Cancer Treatments and Mutations","Neuroendocrine Tumor Research Advances","Acrylamides","Aniline Compounds","Carcinoma, Non-Small-Cell Lung","ErbB Receptors","Humans","Lung Neoplasms","Indoles","Pyrimidines"],"mesh_terms":["Acrylamides","Aniline Compounds","Carcinoma, Non-Small-Cell Lung","Humans","Indoles","Lung Neoplasms","Pyrimidines","ErbB Receptors"],"keywords":["Osimertinib","Lung cancer","Epidermal growth factor receptor","Medicine","Erlotinib","Cancer research","Oncology","Carcinoma","Cancer","Pathology","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:28:52.065261Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}